Liang et al,55 2002 | Prospective, non-randomised; stage IV CRC | High-dose 5-FU/leucovorin | 52 | Better survival in patients with MSI-H tumours who received chemotherapy |
Ribic et al,56 2003 | Retrospective MSI analysis of tumours from patients who participated in a multicentre RCT 20–25 years ago; CRC stage II/III | 5-FU/leucovorin or levamisol | 95 | No survival differences |
Carethers et al,57 2004 | Retrospective, consecutive patients; CRC stage II/III | 5-FU-based | 36 | No survival differences |
De Vos et al,58 2004 | Retrospective, CRC stage III patients from families with HNPCC | 5-FU/leucovorin or levamisol | 92 | No survival differences |
Fallik et al,59 2003 | Non-randomised controlled trial; CRC stage IV | Irinotecan (CPT11) | 7 | 3 partial and 1 complete response |